Similarly, the two phase III trials (Checkmate-498 and 548) investigating nivolumab in the first-line setting (MGMT-unmethylated and MGMT-methylated GBM, respectively) did not show benefits in terms of progression-free and overall survival [35,36]. The gene discussed is MGMT; the disease is glioblastoma.